Literature DB >> 28259484

Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study.

Subra Kugathasan1, Lee A Denson2, Thomas D Walters3, Mi-Ok Kim4, Urko M Marigorta5, Melanie Schirmer6, Kajari Mondal7, Chunyan Liu4, Anne Griffiths3, Joshua D Noe8, Wallace V Crandall9, Scott Snapper10, Shervin Rabizadeh11, Joel R Rosh12, Jason M Shapiro13, Stephen Guthery14, David R Mack15, Richard Kellermayer16, Michael D Kappelman17, Steven Steiner18, Dedrick E Moulton19, David Keljo20, Stanley Cohen21, Maria Oliva-Hemker22, Melvin B Heyman23, Anthony R Otley24, Susan S Baker25, Jonathan S Evans26, Barbara S Kirschner27, Ashish S Patel28, David Ziring29, Bruce C Trapnell30, Francisco A Sylvester17, Michael C Stephens31, Robert N Baldassano32, James F Markowitz33, Judy Cho34, Ramnik J Xavier35, Curtis Huttenhower6, Bruce J Aronow36, Greg Gibson5, Jeffrey S Hyams37, Marla C Dubinsky34.   

Abstract

BACKGROUND: Stricturing and penetrating complications account for substantial morbidity and health-care costs in paediatric and adult onset Crohn's disease. Validated models to predict risk for complications are not available, and the effect of treatment on risk is unknown.
METHODS: We did a prospective inception cohort study of paediatric patients with newly diagnosed Crohn's disease at 28 sites in the USA and Canada. Genotypes, antimicrobial serologies, ileal gene expression, and ileal, rectal, and faecal microbiota were assessed. A competing-risk model for disease complications was derived and validated in independent groups. Propensity-score matching tested the effect of anti-tumour necrosis factor α (TNFα) therapy exposure within 90 days of diagnosis on complication risk.
FINDINGS: Between Nov 1, 2008, and June 30, 2012, we enrolled 913 patients, 78 (9%) of whom experienced Crohn's disease complications. The validated competing-risk model included age, race, disease location, and antimicrobial serologies and provided a sensitivity of 66% (95% CI 51-82) and specificity of 63% (55-71), with a negative predictive value of 95% (94-97). Patients who received early anti-TNFα therapy were less likely to have penetrating complications (hazard ratio [HR] 0·30, 95% CI 0·10-0·89; p=0·0296) but not stricturing complication (1·13, 0·51-2·51; 0·76) than were those who did not receive early anti-TNFα therapy. Ruminococcus was implicated in stricturing complications and Veillonella in penetrating complications. Ileal genes controlling extracellular matrix production were upregulated at diagnosis, and this gene signature was associated with stricturing in the risk model (HR 1·70, 95% CI 1·12-2·57; p=0·0120). When this gene signature was included, the model's specificity improved to 71%.
INTERPRETATION: Our findings support the usefulness of risk stratification of paediatric patients with Crohn's disease at diagnosis, and selection of anti-TNFα therapy. FUNDING: Crohn's and Colitis Foundation of America, Cincinnati Children's Hospital Research Foundation Digestive Health Center.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28259484      PMCID: PMC5719489          DOI: 10.1016/S0140-6736(17)30317-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  28 in total

1.  A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.

Authors:  Kathleen Machiels; Marie Joossens; João Sabino; Vicky De Preter; Ingrid Arijs; Venessa Eeckhaut; Vera Ballet; Karolien Claes; Filip Van Immerseel; Kristin Verbeke; Marc Ferrante; Jan Verhaegen; Paul Rutgeerts; Séverine Vermeire
Journal:  Gut       Date:  2013-09-10       Impact factor: 23.059

2.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

Review 3.  Fibrogenesis and fibrosis in inflammatory bowel diseases: Good and bad side of same coin?

Authors:  Mariabeatrice Principi; Floriana Giorgio; Giuseppe Losurdo; Viviana Neve; Antonella Contaldo; Alfredo Di Leo; Enzo Ierardi
Journal:  World J Gastrointest Pathophysiol       Date:  2013-11-15

4.  Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment.

Authors:  N Vande Casteele; V Ballet; G Van Assche; P Rutgeerts; S Vermeire; A Gils
Journal:  Gut       Date:  2011-02-17       Impact factor: 23.059

5.  Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011.

Authors:  Christine Rungoe; Ebbe Langholz; Mikael Andersson; Saima Basit; Nete M Nielsen; Jan Wohlfahrt; Tine Jess
Journal:  Gut       Date:  2013-09-20       Impact factor: 23.059

6.  High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis.

Authors:  Kanji Uchida; Koh Nakata; Bruce C Trapnell; Takahiro Terakawa; Emi Hamano; Ayako Mikami; Ikumi Matsushita; John F Seymour; Masayoshi Oh-Eda; Ikuo Ishige; Yoshinobu Eishi; Takayuki Kitamura; Yoshitsugu Yamada; Kazuo Hanaoka; Naoto Keicho
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

7.  Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn's disease treated with anti-tumor necrosis factor antibodies.

Authors:  Piotr Eder; Michal Michalak; Katarzyna Katulska; Liliana Lykowska-Szuber; Iwona Krela-Kazmierczak; Kamila Stawczyk-Eder; Katarzyna Klimczak; Aleksandra Szymczak; Krzysztof Linke
Journal:  Sci Rep       Date:  2015-05-20       Impact factor: 4.379

8.  Dissecting Allele Architecture of Early Onset IBD Using High-Density Genotyping.

Authors:  David J Cutler; Michael E Zwick; David T Okou; Sampath Prahalad; Thomas Walters; Stephen L Guthery; Marla Dubinsky; Robert Baldassano; Wallace V Crandall; Joel Rosh; James Markowitz; Michael Stephens; Richard Kellermayer; Marian Pfefferkorn; Melvin B Heyman; Neal LeLeiko; David Mack; Dedrick Moulton; Michael D Kappelman; Archana Kumar; Jarod Prince; Promita Bose; Kajari Mondal; Dhanya Ramachandran; John F Bohnsack; Anne M Griffiths; Yael Haberman; Jonah Essers; Susan D Thompson; Bruce Aronow; David J Keljo; Jeffrey S Hyams; Lee A Denson; Subra Kugathasan
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

9.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Authors:  Luke Jostins; Stephan Ripke; Rinse K Weersma; Richard H Duerr; Dermot P McGovern; Ken Y Hui; James C Lee; L Philip Schumm; Yashoda Sharma; Carl A Anderson; Jonah Essers; Mitja Mitrovic; Kaida Ning; Isabelle Cleynen; Emilie Theatre; Sarah L Spain; Soumya Raychaudhuri; Philippe Goyette; Zhi Wei; Clara Abraham; Jean-Paul Achkar; Tariq Ahmad; Leila Amininejad; Ashwin N Ananthakrishnan; Vibeke Andersen; Jane M Andrews; Leonard Baidoo; Tobias Balschun; Peter A Bampton; Alain Bitton; Gabrielle Boucher; Stephan Brand; Carsten Büning; Ariella Cohain; Sven Cichon; Mauro D'Amato; Dirk De Jong; Kathy L Devaney; Marla Dubinsky; Cathryn Edwards; David Ellinghaus; Lynnette R Ferguson; Denis Franchimont; Karin Fransen; Richard Gearry; Michel Georges; Christian Gieger; Jürgen Glas; Talin Haritunians; Ailsa Hart; Chris Hawkey; Matija Hedl; Xinli Hu; Tom H Karlsen; Limas Kupcinskas; Subra Kugathasan; Anna Latiano; Debby Laukens; Ian C Lawrance; Charlie W Lees; Edouard Louis; Gillian Mahy; John Mansfield; Angharad R Morgan; Craig Mowat; William Newman; Orazio Palmieri; Cyriel Y Ponsioen; Uros Potocnik; Natalie J Prescott; Miguel Regueiro; Jerome I Rotter; Richard K Russell; Jeremy D Sanderson; Miquel Sans; Jack Satsangi; Stefan Schreiber; Lisa A Simms; Jurgita Sventoraityte; Stephan R Targan; Kent D Taylor; Mark Tremelling; Hein W Verspaget; Martine De Vos; Cisca Wijmenga; David C Wilson; Juliane Winkelmann; Ramnik J Xavier; Sebastian Zeissig; Bin Zhang; Clarence K Zhang; Hongyu Zhao; Mark S Silverberg; Vito Annese; Hakon Hakonarson; Steven R Brant; Graham Radford-Smith; Christopher G Mathew; John D Rioux; Eric E Schadt; Mark J Daly; Andre Franke; Miles Parkes; Severine Vermeire; Jeffrey C Barrett; Judy H Cho
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

10.  Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study.

Authors:  Isabelle Cleynen; Gabrielle Boucher; Luke Jostins; L Philip Schumm; Sebastian Zeissig; Tariq Ahmad; Vibeke Andersen; Jane M Andrews; Vito Annese; Stephan Brand; Steven R Brant; Judy H Cho; Mark J Daly; Marla Dubinsky; Richard H Duerr; Lynnette R Ferguson; Andre Franke; Richard B Gearry; Philippe Goyette; Hakon Hakonarson; Jonas Halfvarson; Johannes R Hov; Hailang Huang; Nicholas A Kennedy; Limas Kupcinskas; Ian C Lawrance; James C Lee; Jack Satsangi; Stephan Schreiber; Emilie Théâtre; Andrea E van der Meulen-de Jong; Rinse K Weersma; David C Wilson; Miles Parkes; Severine Vermeire; John D Rioux; John Mansfield; Mark S Silverberg; Graham Radford-Smith; Dermot P B McGovern; Jeffrey C Barrett; Charlie W Lees
Journal:  Lancet       Date:  2015-10-18       Impact factor: 202.731

View more
  150 in total

1.  Positioning Biologic Therapies in the Management of Pediatric Inflammatory Bowel Disease.

Authors:  Jessica Breton; Arthur Kastl; Maire A Conrad; Robert N Baldassano
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-08

2.  Association Between Plasma Level of Collagen Type III Alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn's Disease.

Authors:  Cortney R Ballengee; Ryan W Stidham; Chunyan Liu; Mi-Ok Kim; Jarod Prince; Kajari Mondal; Robert Baldassano; Marla Dubinsky; James Markowitz; Neal Leleiko; Jeffrey Hyams; Lee Denson; Subra Kugathasan
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-10       Impact factor: 11.382

3.  Blood-Derived DNA Methylation Signatures of Crohn's Disease and Severity of Intestinal Inflammation.

Authors:  Hari K Somineni; Suresh Venkateswaran; Varun Kilaru; Urko M Marigorta; Angela Mo; David T Okou; Richard Kellermayer; Kajari Mondal; Dawayland Cobb; Thomas D Walters; Anne Griffiths; Joshua D Noe; Wallace V Crandall; Joel R Rosh; David R Mack; Melvin B Heyman; Susan S Baker; Michael C Stephens; Robert N Baldassano; James F Markowitz; Marla C Dubinsky; Judy Cho; Jeffrey S Hyams; Lee A Denson; Greg Gibson; David J Cutler; Karen N Conneely; Alicia K Smith; Subra Kugathasan
Journal:  Gastroenterology       Date:  2019-02-16       Impact factor: 22.682

Review 4.  Redefining the IBDs using genome-scale molecular phenotyping.

Authors:  Terrence S Furey; Praveen Sethupathy; Shehzad Z Sheikh
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-05       Impact factor: 46.802

5.  Therapeutics for Inflammatory Bowel Diseases in Children and Adolescents: A Focus on Biologics and an Individualized Treatment Paradigm.

Authors:  Suruchi Batra; Laurie S Conklin
Journal:  Handb Exp Pharmacol       Date:  2020

6.  IBD: Risk stratification in children with Crohn's disease.

Authors:  Iain Dickson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-04-12       Impact factor: 46.802

7.  Prioritizing Crohn's disease genes by integrating association signals with gene expression implicates monocyte subsets.

Authors:  Kyle Gettler; Mamta Giri; Ephraim Kenigsberg; Jerome Martin; Ling-Shiang Chuang; Nai-Yun Hsu; Lee A Denson; Jeffrey S Hyams; Anne Griffiths; Joshua D Noe; Wallace V Crandall; David R Mack; Richard Kellermayer; Clara Abraham; Gabriel Hoffman; Subra Kugathasan; Judy H Cho
Journal:  Genes Immun       Date:  2019-01-29       Impact factor: 2.676

8.  Microbiota-sensitive epigenetic signature predicts inflammation in Crohn's disease.

Authors:  Daniel Kelly; Michael Kotliar; Vivienne Woo; Sajjeev Jagannathan; Jordan Whitt; Jessica Moncivaiz; Bruce J Aronow; Marla C Dubinsky; Jeffrey S Hyams; James F Markowitz; Robert N Baldassano; Michael C Stephens; Thomas D Walters; Subra Kugathasan; Yael Haberman; Nambirajan Sundaram; Michael J Rosen; Michael Helmrath; Rebekah Karns; Artem Barski; Lee A Denson; Theresa Alenghat
Journal:  JCI Insight       Date:  2018-09-20

Review 9.  Gastrointestinal tract microbiota modifications in systemic sclerosis.

Authors:  Elizabeth R Volkmann; Anna-Maria Hoffmann-Vold
Journal:  Eur J Rheumatol       Date:  2019-12-19

10.  Colonic epithelial miR-31 associates with the development of Crohn's phenotypes.

Authors:  Benjamin P Keith; Jasmine B Barrow; Takahiko Toyonaga; Nevzat Kazgan; Michelle Hoffner O'Connor; Neil D Shah; Matthew S Schaner; Elisabeth A Wolber; Omar K Trad; Greg R Gipson; Wendy A Pitman; Matthew Kanke; Shruti J Saxena; Nicole Chaumont; Timothy S Sadiq; Mark J Koruda; Paul A Cotney; Nancy Allbritton; Dimitri G Trembath; Francisco Sylvester; Terrence S Furey; Praveen Sethupathy; Shehzad Z Sheikh
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.